Acquisition Opportunity Following Charles River Labs’ acquisition of PathoQuest, leverage enhanced end-to-end biosafety testing capabilities and cross-sell NGS-based viral safety and genetic characterization services to clients of both organizations, highlighting expanded GMP-compliant, animal-free assays.

NGS Advantage Target biopharma manufacturers of gene therapies, monoclonal antibodies, vaccines, and raw materials seeking faster release and safer characterizations, emphasizing iDTECT platform’s rapid, compliant, and scalable NGS-based biosafety testing.

Global Footprint Position PathoQuest’s facilities in Paris and Wayne, PA as global access points for international clients needing GMP-certified biosafety testing, enabling regional regulatory readiness and faster time-to-market across markets.

Strategic Partnerships Leverage past collaborations such as the Oxford Nanopore partnership to propose integrated sequencing workflows and co-developed testing solutions, opening doors for joint offerings with potential sponsor or client collaborations.

Growth Signals Capitalize on recent leadership additions and market education initiatives like the Next-Gen Biosafety Masterclass to generate leads, position as a thought leader, and convert interest into pilot testing engagements for new clients.